Yoon-Sik Kang/LinkedIn
Jul 6, 2026, 14:17
Yoon-Sik Kang: Low-Blood-Loss Hernia Repair Aims to Reduce Perioperative Risk
Yoon-Sik Kang, Director, Hernia Surgeon at Gibbeum Hospital, shared a post on LinkedIn:
“The mean intraoperative blood loss in Kang Repair is 1–2 cc — less than a teaspoon.
For most patients this number sounds like trivia.
For one specific population it is the reason the surgery is possible at all: those on anticoagulation.
Why ‘bloodless’ matters clinically:
- Standard surgical practice interrupts anticoagulation perioperatively — carrying real thromboembolic risk
- Kang Repair: no interruption required, regardless of warfarin, DOACs, aspirin, or clopidogrel
- Mean blood loss 1–2 cc holds across the 20,000 plus case series, including elderly and complex cases
- One Jehovah’s Witness patient flew from South Africa specifically because zero transfusion risk was a religious necessity
Atrial fibrillation, coronary stents, prosthetic valves, prior PE/DVT — these patient populations have hernias too.
They deserve a repair that does not require trading anticoagulation safety for surgical safety.
Mesh was reclassified as high-risk in Australia (2018); UK reports document 100,000 plus complication cases.
Stay updated with Hemostasis Today.
-
Aug 24, 2026, 15:15Jim Hoffman: Could Targeting NETosis Reduce Long-Term Risk After STEMI?
-
Aug 24, 2026, 14:58Danny Hsu: Rethinking Bleeding Risk in Patients on Anticoagulation
-
Aug 24, 2026, 14:18The Way to a Safer Workplace for People With Bleeding Disorders – EHC
-
Aug 24, 2026, 14:09Stuart Andrew: NHS Blood and Transplant Strengthening the Blood Supply
-
Aug 24, 2026, 14:05Edward Lee Carter: Anticoagulation Stewardship is Moving From Recommendation to Measurement
-
Aug 24, 2026, 13:58Meera Chitlur: Transforming Care for Heavy Menstrual Bleeding at Children’s Hospital of Michigan
-
Aug 24, 2026, 13:49Heghine Khachatryan: Prepartum Acquired Hemophilia A and the Challenge of Maternal and Neonatal Bleeding
-
Aug 24, 2026, 13:44Neeraj Songara: Therapeutic Plasma Exchange in Severe Guillain–Barré Syndrome
-
Aug 24, 2026, 13:42Pall T. Onundarson: The Role of Measuring Treatment Effect in Optimizing DOAC and Warfarin Therapy